New mRNA vaccine candidates for RSV enter human testing
NCT ID NCT07071558
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested six different mRNA vaccine formulations against respiratory syncytial virus (RSV) in 240 healthy adults aged 18 to 49. The goal was to check safety and how well the vaccines trigger an immune response. Each participant received a single shot and was followed for about six months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mRNA vaccine targeting RSV (respiratory syncytial virus)
- What this could lead to
- If successful, this could help develop a safe and effective mRNA vaccine to protect against RSV, a common respiratory virus.
- What could go wrong
- This is an early phase 1 study focused on safety, not effectiveness. The vaccine may not produce strong immunity or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS IMMUNIZATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site # 0361001
Camberwell, Victoria, 3124, Australia
-
Site # 0361002
Bayswater, Victoria, 3153, Australia
-
Site # 0361003
Wollongong, New South Wales, 2500, Australia
-
Site # 0361004
Southport, Queensland, 4215, Australia
-
Site # 0361005
Morayfield, Queensland, 4506, Australia
-
Site # 0361006
Brisbane, Queensland, 4006, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.